NOTCH1 mutations are more frequent in CLL patients on BTK inhibitors, suggesting that therapeutic blockade of proximal BCR kinases may select for clones in which NOTCH1 substitutes as an alternative amplifier of PI3K/AKT signaling. Here, BCR is linked to B-cell chronic lymphocytic leukemia.